- Federal regulators have approved a new injectable medication for wet age-related macular degeneration and diabetic macular edema.
- 这两种疾病是视力丧失的主要原因之一。
- 与当前使用的药物相比，新的药物Vabysmo的注射治疗频率较低。
- 专家说，新药物还将为有眼病的人提供更多选择。
食品药品监督管理局（FDA）有得到正式认可的a new drug for treating two conditions that cause vision loss.
The drug Vabysmo (faricimab-svoa) treats wet age-related macular degeneration (AMD) and diabetic macular edema (DME), two of the leading causes of vision loss.
It’s the first injectable eye medication that has been approved for the treatment of both conditions and offers a more flexible dosing regimen than medications currently used.
“ Vabysmo代表了眼科迈出的重要一步。它是批准眼睛的第一个双特异性抗体，也是治疗视网膜疾病（如湿AMD和糖尿病黄斑水肿）的主要进步，”Dr. Charles C. Wykoff, a Vabysmo phase 3 investigator and director of research at Retina Consultants of Texas, said in apress release.
他补充说：“借助Vabysmo，我们现在有机会为患者提供一种可以改善视力的药物，随着时间的推移，注射量减少，可能会降低治疗负担。”
Experts who spoke with Healthline say the drug is good news for people living with AMD and DME.
“我们的药物已经正常工作并治疗了这些疾病。但是他们遇到的问题是患者必须经常接受这些治疗。现在，人们希望……可以扩展治疗。这是一个好消息，”Hossein Ameri博士, an ophthalmologist with the USC Roski Eye Institute at Keck Medicine of USC.
“另一个是，当您在同一领域有更多药物时，您有更多选择。” Ameri告诉Healthline。雷竞技app官网
Wet age-related macular degeneration is one of the
In wet AMD, bleeding, leaking, and scarring are caused by the growth of abnormal blood vessels behind the retina. This causes people to lose their central vision, which is necessary to see sharp details.
在糖尿病性黄斑水肿中，在视网膜壁中发现的血管会削弱并形成凸起的小袋。这些会泄漏血液和其他液体，这导致视网膜的一部分肿胀并引起视力问题。
Without adequate treatment, people living with wet AMD and DME face a gradual loss of their central vision.
“In the absence of effective control, macular degeneration and diabetic macular edema cause progressive loss of central vision, leading to difficulty reading, potential loss of adequate vision for driving, loss of ability to discern faces, but rarely to loss of peripheral vision, such that vision generally remains adequate for safe self-care and walking unassisted,” said霍华德·R·克劳斯博士是一名外科神经浏览医生，以及加利福尼亚州圣莫尼卡普罗维登斯圣约翰健康中心圣约翰癌症研究所眼科和神经外科临床教授。
“湿的黄斑变性和糖尿病性黄斑水肿会影响越来越多的人，并且是全球失明的主要原因。因此，非常欢迎所有可用于治疗这些疾病的突破性药物。”克劳斯告诉Healthline。雷竞技app官网
Vabysmo的目标是针对两种途径，这些途径被认为在视力丧失中发挥作用：ANG-2和VEGF-A。
By inhibiting these pathways, the drug reduces inflammation and leakage from blood vessels.
While similar medications already exist, they require more frequent eye injections. Treatment using Vabysmo involves fewer regular eye injections.
对于患有湿AMD的人，该方案最初涉及四个每月注射，然后根据结果，每2、3或4个月进行进一步治疗。
People with DME are also given four monthly injections at first, with follow-up injections every 1 to 4 months based on how the person responds.
“Most patients respond to current treatments, but the need for regular follow-up and sometimes eye injections remain a major challenge. Imagine someone who missed his/her treatment because he/she got sick or went on a family vacation, then lost vision,”Dr. Radwan Ajlan堪萨斯大学卫生系统眼科诊所的眼科医生告诉Healthline。雷竞技app官网
“(Vabysmo) is helpful because it may decrease the number of injections patients receive,” he added.